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Abstract 
Congenital prothrombin deficiency is an extremely rare hemorrhagic disorder 
with estimated prevalence of 1 per 2,000,000 in the general population. Since 
the disorder is an autosomal recessive disorder, the disorder is more frequent 
in areas with high rate of consanguinity. Clinical manifestations of the disorder 
are highly variable ranging from mild bleeding episodes to severe life-
threatening hemorrhages. The disorder can be diagnosed based on routine and 
specific tests. Deficiency in concentration of specific factor II (FII) is available, 
but patients can receive fresh frozen plasma (FFP) and prothrombin complex 
concentrate (PCC). Traditionally patients with prothrombin deficiency receive 
on-demand therapy, but secondary prophylaxis can be used for those patients 
with high risk of severe life-threatening bleeding. With timely diagnosis and 
appropriate management of disorder quality of life in these patients can 
significantly improve. 
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Introduction 
Prothrombin deficiency or factor II (FII) 
deficiency is an extremely rare hemorrhagic disorder 
with estimated incidence of one per 2 million in the 
general population. The disorder is more common in 
areas with high rate of consanguinity. Patients with FII 
deficiency (FIID) present various clinical presentation 
ranges from asymptomatic conditions to severe life-
threatening bleeding. Patients may present mild 
bleeding episodes such as epistaxis, gum bleeding and 
bruising to severe hemorrhages such as intracranial 
hemorrhage and gastrointestinal bleeding. Patients 
with FIID usually require on-demand replacement 
therapy, but prophylaxis may be used for those patients 
at high risk of severe life-threatening hemorrhages. 
Diagnosis of disorder is made based on simultaneous 
prolongation of prothrombin time (PT) and activated 
partial thromboplastin time (aPTT) and decreased FII 
activity. FII antigen assay can be used to determine the 
type of disorder (type I and type II). 
 Different therapeutic choices are available for 
these patients including fresh frozen plasma (FFP) and 
prothrombin complex concentrate (PCC), but no 
specific concentrate is available. With appropriate 
management of disorder the rate of morbidity and 
mortality can significantly decreased and the quality of 
life of patients can increased.   
Prothrombin structure and activation  
Prothrombin, or coagulation FII, circulates in 
the blood at a concentration of 0.1 mg/ml, as an 
inactive precursor of α-thrombin which synthesized in 
liver and released into the blood stream (1, 2). The 
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prothrombin is a 70-kD glycoprotein (579-residues), 
composed of a N-terminal Gla domain (10 γ-
carboxyglutamic residues), k1 domain (Kringle-1), k2 
domain (Kringle-2), and a serine protease catalytic 
domain with A and B chains (figure 1) (2-4). 
Prothrombin to thrombin conversion requires 
two cleavages at Arg273-Thr274 and Arg322-Ile323 
sites (1, 5, 6).  Since cleavage at different sites is 
necessary for prothrombin activation and conversion to 
thrombin, there are three possible pathways for a 
thrombin formation (figure 2) (6-8). In coagulation 
cascade for prothrombin to α-thrombin conversion, this 
protein must be cleaved by prothrombinase complex 
(consists of activated FXa, cofactor Va, 
phosphatidylserine and calcium) (4, 9). In the first 
pathway (reaction A in figure 2), FXa initially cleaves 
prothrombin at position Arg273-Thr274 and yields the 
fragment 1.2 (F1.2), as an activation peptide and a 
catalytically inactive intermediate species known as 
prethrombin 2 (Pre2). F1.2 comprised of Gla and 
kringle domains, and Pre2 intermediate molecule 
comprised of A-chain and B-chain with band at 
Arg322–Ile323 intact, which is necessary for making 
Pre2 catalytically inactive. Further proteolysis of this 
band (reaction B) converts Pre2 to α-thrombin with 
35.5 kDa molecular weight, which composed of A-
chain (36-residues) and a catalytic B-chain (259-
residues) linked by a disulfide bridge C1-C122 (6-8). 
α-thrombin contains four disulfide bands, therefore A 
and B chains can covalently link to one of them (C1-
C122) and three bonds, C48-C52, C168-C182 and 
C191-C220 are present as intra-chain disulfide bridges 
in B-chain (10, 11). 
In the second pathway (figure 2, reaction C), 
FXa cleaves prothrombin at Arg322-Ile323 site and 
generates an intermediate molecular protein known as 
meizothrombin (mIIa) which is a catalytically active 
molecule that then (reaction D) is converted to F1.2 
and α-thrombin followed by further proteolysis of 
meizothrombin by FXa at Arg273-Thr274 site (2, 6, 7). 
In the third pathway (reaction E), prothrombin 
molecule produces α-thrombin without releasing 
intermediate molecules from the enzyme. This reaction 
is performed by prothrombinase complex and, since it 
occurs simultaneously and quickly, prothrombin is 
converted directly to thrombin (6-8).  
Due to catalytic domain, α-thrombin is very 
similar to trypsin and other similar proteases (all of 
them cleave proteins at ARG residues) (9, 12). Alpha-
thrombin, which composed of two β-barrels and helix, 
has a special structure due to its active site, exosite, and 
electrostatic fields with positive and negative charges 
(figure 3). The active site is located in the central part 
of α-thrombin. Three residues, Ser195, His57, and 
Asp102, which are located between both β-barrels, 
comprised the active site groove extending across both 
β-barrels perpendicular to the junction (9, 12). 
Due to 27 additional residues in thrombin 
compared to chymotrypsin, large loops are formed on 
thrombin surface, especially around the active site. 
Two interesting loops that make active site groove 
deep and narrow are 60-loop and 149-loop (also known 
as autolysis loop, 147-loop and γ-loop) (9, 13-15). 
Sixty-loop is more hydrophobic and can interact with 
hydrophobic residues, but 149-loop is hydrophilic 
(14). The function of these loops is to block the access 
of macromolecular proteins, substrates or inhibitors to 
the active site and the specificity of thrombin (9, 13). 
From electrostatic fields, three patches are more 
important, one with negative charge and two with 
positive charge. The negative patch is located around 
the active site in the packet S1 with D819 and E192 (9, 
13). The first positive patch is away from the active site 
and located on the outer side and is called anion 
binding exosite I (ABE-I) (8, 16). This patch can 
directly or indirectly interacts with many important 
proteins, including thrombomodulin (TM), protease 
activated receptors 1 (PAR1), PAR3, FV, FVIII, FXIII, 
and especially fibrinogen that is also known as 
fibrinogen binding site due to binding to fibrinogen (8, 
15). In contrast to the second electrostatic patch with 
positive charge is called anion binding exosite (ABEII) 
(8, 16), which is the main site for the binding of poly-
anion ligands such as heparin and that is why it is also 
known as heparin binding site (8, 15). 
An important point is that fibrinogen and PAR1 
binds to thrombin at active site and exosite I. Protein C 
(pro-C) interacts with binding site around fibrinogen or 
PAR1, but thrombomodulin binds to exosite 1 (8, 15). 
Due to the overlaps of the binding sites of TM, 
Fibrinogen and PAR1, TM can completely interrupt 
the procoagulant effect of thrombin and induce 
cleavage of protein C and enhance thrombin 
anticoagulant property (8, 15). 
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Sodium binding site is another thrombin surface 
patch, where NA+ binding to thrombin is considered as 
one of the thrombin regulator mechanisms (8, 13). As 
thrombin is an allosteric enzyme, this interaction 
affects thrombin function making it "slow" or "fast". 
These thrombin forms are characterized by the absence 
("slow" form) or presence ("fast" form) of NA+ ion. 
Converting slow thrombin to fast form increased its 
binding to substrates such as fibrinogen and its 
catalytic and procoagulant functions (8, 13). 
 
Prothrombin deficiency (Factor II Deficiency) 
Prothrombin deficiency (FIID) is a rare 
coagulation disorder, with a prevalence of about 
1:2000000 (38). Prothrombin deficiency can be 
diagnosed and classified by routine laboratory tests 
such as PT and aPTT, FII activity and antigen assays 
(39). According to the measurement of functional and 
antigenic plasma levels, FIID has been classified into 
two types: hypoprothrombinemia (type I) which is also 
known as true deficiency that is associated with low 
 
Figure 1.  Schematic structure of human prothrombin. Prothrombin consists of two parts, leader peptide (43 residues) and 
mature protein (579 residues). Mature protein includes Gla domain, k1 domain (kringle1 domain), k2 domain (kringle2 
domain), A-chain (α-thrombin light chain) and B-chain (α-thrombin heavy chain; catalytic domain; serine protease 
domain). 
 
Figure 2.  Schematic activation of human prothrombin. there are three pathways for prothrombin thrombin 
conversion. First pathway: A. activated factor X (factor Xa)a cleaves prothrombin after Arg273 amino acid and  yields 
fragment 1.2 (F1.2) and prothrombin 2 (pre2). B. Further proteolysis of pre2 after Arg322 amino acid generates α-thrombin 
consists of A and B chains. Second pathway: C. cleavage of prothrombin at Arg322 position yields catalytically active 
intermediate Meizothrombin (mIIa). D. factor Xa cleaves mIIa after Arg273 amino acid and generate α-thrombin and F1.2. 
Third pathway: E. Simultaneously cleavage of prothrombin at Arg273 amino acid and Arg322 amino acid, produces F1.2 
and α-thrombin. 
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antigen level and reduced plasma activity of FII. 
Dysprothrombinemia (type II) is associated with low 
activity and normal or near normal antigen level (19, 
38, 39). Based on the FII level, FIID can be classified 
into three forms, severe (less than 5%), moderate (5-
10%) and mild (more than 10%) (39). Clinical 
manifestations of patients with FIID are highly 
variable (38). Bleeding complications include 
spontaneous hematomas/bruising, gastrointestinal 
hemorrhages, menorrhagia, intracerebral hemorrhage, 
Post-dental extraction bleeding and post-surgical 
bleeding  (38, 39). 
Clinical manifestations 
Complete absence of prothrombin has not been 
reported due to its necessity for being alive. 
Investigations revealed that mice with knockout 
prothrombin gene show embryonic lethally and 
neonatal death (40). There is a wide spectrum of 
bleeding episodes among patients with FIID ranges 
from mild episodes to severe life-threatening 
presentations. These episodes may be vary from patient 
to patient even in those who are affected by same 
mutation (42). However, due to rarity of FIID, there is 
little information about patients suffering from this 
disorder (43).  
Severe deficiency of prothrombin is 
characterized by less than 5% plasma level in 
homozygote or compound heterozygote patients and 
manifests with severe bleeding including post-surgical 
bleeding, mucosal bleeding and subcutaneous and 
muscle hematoma. Gastrointestinal bleeding have been 
reported in only a few cases (44). Hematoma and 
spontaneous bruising are the most common 
manifestations of the disorder (42, 45, 46). 
Hemarthrosis and post-dental extraction bleeding are 
less common. Menorrhagia is a common symptom that 
can be observed among ~20% of homozygote women 
(47). Generally, the most common clinical 
manifestations in patients with FIID are epistaxis, 
prolonged and heavy menstruation, bleeding in joints 
and muscles and bleeding from mouth and gums. 
Gastrointestinal bleeding, umbilical cord bleeding and 
bleeding after major or minor surgeries are 
occasionally reported in these patients (48), while 
severe life-threatening bleeding such as intracranial 
hemorrhage are reported in less than 10% of patients 
(49).  
In an investigation conducted in Iranian patients 
with prothrombin disorders, 11 out of 14 patients had 
hypothrombinemia with 4-10% prothrombin level and 
3 were diagnosed with dysprothrombinemia. 
Hemarthrosis and muscle hematoma were the most 
common severe manifestations among these patients. 
Intracranial hemorrhage was reported in one case and 
 
Figure 3.  X-ray structure of α-thrombin with PPACK. In the central part of the structure, the active site is located with 
PPACK inhibitor (stick model). PPACK (D-Phe-Pro-Arg-methyl-ketone) is the small covalent inhibitor. Exosite I (ABE-
I; fibrinogen binding site; positively charge patch) is located in the northwest of active site and Exosite II  is located in the 
southeast of active site.  𝑵𝒂+ binding site shown in the southwest of active site. PDB of prothrombin crystal structure 
downloaded from Research Co laboratory for Structural Bioinformatics (RCSB) protein data bank (www.pdb.org). 
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umbilical cord bleeding had observed in two neonates 
(50). In a study on 26 Italian patients with 
hypothrombinemia similar clinical presentations were 
observed and mucosal bleeding, soft tissue hematoma 
and hemarthrosis were reported as relatively common 
presentations (51).  
Heterozygote patients with 30% to 60% 
prothrombin plasma level are usually asymptomatic. 
However, excessive bleeding after trauma, tooth 
extraction and surgical procedures may occur. Patients 
with dysprothrombinemia show different bleeding 
tendency that is usually less severe than 
hypoprothrombinemia (47). 
Molecular basis 
Prothrombin (coagulation FII) is a single chain 
72 kDa protein expressed primarily in liver encoded by 
a 21 kb gene located on chromosome number 11 and 
has 14 exons (52). Thirty two different prothrombin 
causing mutations were identified until 2000, but the 
number is increased to more than 40, so far (47, 43-45). 
The majority of these mutations is occur in catalytic 
region, while some of them disrupt regulatory domains 
including anion-binding exosite-I, Na+ binding loop 
and light A chain. Most of the mutations that resulting 
in hypoprothrombinemia are missenses, but a number 
of nonsense mutations causing stop codon and a single 
nucleotide deletion are also identified (47). More than 
17 mutations have been described in 
dysprothrombinemia; all of them are missense 
mutations. These mutations result in amino acid 
replacement inside the prothrombin cleavage site that 
is activated FX substrate; therefore, mutations interfere 
with serine protease region of thrombin. On the other 
hand, hypothrombinemia-causing mutations are 
usually occur near to Gla and kringle domains and A 
chain (56). 
Homozygote mutations in F2 gene are not 
always lead to severe bleeding; for example Arg76His 
mutation decreases FII activity to less than 20%, but 
causes little bleeding tendency (57). Similarly some 
other mutations including homozygote Glu466Ala and 
compound heterozygote Met337Thr-Arg388His do not 
cause bleeding manifestations (58, 59). In addition, 
mutations like Arg596Leu (called prothrombin 
Yukuhashi) that cause prothrombin with disturbed Na+ 
binding loop, not only do not identify with 
hemorrhagic phenotypes, but also can lead to 
hereditary thrombosis (60). 
Laboratory diagnosis 
PT and aPTT are usually sensitive enough to 
detect coagulation factors abnormalities, but their 
results may be normal in some coagulation factors 
deficiency including fibrinogen, prothrombin and 
FXIII. Therefore, diagnosis of FIID may require 
specific assessments (43, 56). In case of suspicion to 
coagulation factors abnormality based on clinical 
manifestations and family history, an immunological 
assessment for indenting dysprothrombinemia is 
required. In these patients antigenic levels of FII is 
relatively normal without appropriate function. After 
that factor assay or one-stage standard clotting assay 
using specific factor depleted plasma and 
thromboplastin should be conducted (43). There are 
many assessments using different snake venoms for 
prothrombin to thrombin conversion. These 
assessments are including Echis carinatus venom test 
that does not require phospholipids. Taipan venom and 
Textarin venom tests are phospholipid dependent. 
Results of PT and some venom tests are significantly 
lower than antigenic assays in dysprothrombinemia 
(56). Immunological assays are fairly related to 
functional assays in hypoprothrombinemia and both 
are decreased, while dysprothrombinemia is 
characterized by decreased functional assays with 
normal or near normal immunological tests (51, 61). 
Genotyping and molecular assays of FIID are 
conducted only on a few patients. These molecular 
analyses of confirmation of FIID generally only are 
available in research centers (62, 63). 
Diagnosis of prothrombin deficiency may be 
difficult especially in immature neonates due to low 
level of vitamin K. Reassessment after vitamin K 
replacement may be required in these patients (56).  
In many countries, efficient diagnosis of 
bleeding disorders using laboratory tests is very 
difficult due to unavailability and unstandardized 
laboratory assays (64). Due to small amount of 
coagulation factors required for normal results in 
traditional laboratory tests, the factors deficiency could 
be undetectable using these assays. Therefore 
laboratory assessments evaluating general hemostatic 
capacity had been developed (65). These assessments 
including constant thrombin generation, thrombin 
generation test (TGT), clot formation, 
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thromboelastography (TEG) and simultaneous 
generation of thrombin and plasmin, are used to 
hemostasis evaluation (66-70). TGT and TEG are used 
for monitoring of treatment in different bleeding 
episodes in RBD (71). It is crucial to continue to 
undertake attempts for standardize and quality 
assessment of laboratory technologies like TEG and 
TGT; since these strategies can be helpful in 
coagulation deficiencies with high risk of thrombotic 
events during therapeutic periods (43).  
Treatment 
Treatment of FIID should be individualized. 
The purpose is to maintain FII levels as enough as 
required level for normal hemostasis. Traditional 
treatment for patients with FIID is on-demand therapy 
that means beginning of treatment as soon as possible 
afterbleeding, but secondary prophylaxis can be 
considered for those with high risk of life threatening 
bleeding. The dosage and frequency of therapeutic 
agents administration are depend on the minimal level 
of deficient factor, its plasma half-life and type of 
bleeding episodes (43, 62). The main treatment of 
prothrombin deficiency is replacement therapy using 
fresh frozen plasma (FFP) andprothrombin complex 
concentrate (PCC). Moreover, administration of 
antifibrinolytic agents, with or without replacement 
therapy, can be useful in the management of mild 
bleeding episodes. Administration of antifibrinolytic 
agents accompanied by PCC is contraindicated 
because thrombotic complications are potential risk of 
PCC injection and fibrinolysis is the only body 
defending mechanism against undesirable clot 
formation (72). 
Hormonal interference might help to decrease 
menorrhagia by estrogen-progesterone consumption 
(43). For patients with severe bleeding manifestations 
prophylactic treatment should be considered. It 
includes primary and secondary prophylaxes that are 
different in administration timing (before bleeding 
onset to prevent or after bleeding to recurrence 
debarment). In general, due to inadequate information 
about patients with FIID, regular replacement therapy 
should be monitored to prevent thrombotic 
complications (43). 
There is no pure prothrombin concentrate 
available; so PCC is therapeutic choice. Most of PCCs 
are containing therapeutic amounts of three 
coagulation factors: FII, FIX and FX. There are also 
PCCs containing four coagulation factors that have 
FVII in addition to above (73, 74). In absence of a 
proper PCC, viral inactivated FFP can be administered 
as source of prothrombin. Although viral inactivation 
can eliminate blood born infections, other 
complications of blood products injection are remain 
including inhibitor formation, thrombosis and rash 
(43).  
Injection of every single unit of prothrombin 
increases plasma prothrombin level for about 1 IU/dl. 
It seems to 20-30 IU/dl level of prothrombin is 
adequate for normal hemostasis. Administration of 20-
30 IU/kg dose seems effective; however, higher doses 
may be required for life-threatening bleedings 
management. Prothrombin half-life is about 72 hours; 
so the frequency of injections lowered to every 2 or 3 
days (56, 75).  
Severe life-threatening bleeding episodes are 
not observed widely in infancy; however umbilical 
cord bleeding is reported occasionally. Thus primary 
prophylactic replacement therapy does not conduct for 
patients in early infancy (56). Patients with 
cardiovascular diseases are at risk for circulatory 
overload; so it is better to inject PCC instead of FFP in 
these patients (75). 
Conclusion 
This study provides a general overview about 
prothrombin, associated disorders and how to manage 
them. Given the rarity of congenital prothrombin 
deficiency, the information about the disorder is 
limited. We hope this survey could provide an insight 
for better understanding, identification and 
management of FIID.  
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